Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen Inc    BIIB

BIOGEN INC (BIIB)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 07:13am EST
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at tess.stynes@dowjones.com and Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN INC
02/15 BIOGEN : to Present at the 2017 RBC Capital Markets Global Healthcare Conference
02/07 BIOGEN : to Present at the Leerink Partners 6th Annual Global Healthcare Confere..
02/02 BIOGEN INC : Spin off
02/01 BIOGEN : Completes Separation of Global Hemophilia Business, Bioverativ
01/26DJBIOGEN : Profit Skids, Revenue Grows Less Than Expected
01/26 BIOGEN : Reports 2016 Revenues of $11.4 Billion
01/23BIOGEN INC : annual earnings release
01/17 BIOGEN FOURTH QUARTER AND YEAR END 2 : 00 am on January 26, 2017
01/17 SIEMENS HEALTHINEERS : and Biogen Announce Agreement to Jointly Develop New MRI ..
01/17DJBIOGEN : Reaches Settlement and License Agreement for MS Drug
More news
Sector news : Biopharmaceuticals
02:06aDJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/23 Exclusive - Trump says Republican border tax could boost U.S. jobs
More sector news : Biopharmaceuticals
News from SeekingAlpha
02/24 Truxima Fires The Starting Gun In Biosimilar Race To The Bottom
02/23 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q4 2016 Update
02/21 This Biotech ETF Looks Primed To Rally Again
02/20 Tracking John Paulson's Paulson & Company Portfolio - Q4 2016 Update
02/19 Tracking Jeffrey Ubben's ValueAct Portfolio - Q4 2016 Update
Advertisement
Financials ($)
Sales 2017 11 292 M
EBIT 2017 6 114 M
Net income 2017 3 983 M
Debt 2017 610 M
Yield 2017 -
P/E ratio 2017 15,35
P/E ratio 2018 13,79
EV / Sales 2017 5,51x
EV / Sales 2018 5,06x
Capitalization 61 574 M
More Financials
Chart BIOGEN INC
Duration : Period :
Biogen Inc Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Full-screen chart
Technical analysis trends BIOGEN INC
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 322 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Spyridon Artavanis-Tsakonas Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN INC9.10%61 574
CSL LIMITED17.26%41 358
ALEXION PHARMACEUTICAL..7.51%29 546
BIOMARIN PHARMACEUTICA..5.64%15 051
GRIFOLS SA10.28%13 922
3SBIO INC18.82%2 946
More Results